Ibuprofen product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 1 July 2025 - 12:10
Ibuprofen product-specific bioequivalence guidance
Dolutegravir product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 1 July 2025 - 12:00
Dolutegravir product-specific bioequivalence guidance
Levothyroxine product-specific bioequivalence guidance
Submitted by Anonymous (not verified) on 1 July 2025 - 11:55
Levothyroxine product-specific bioequivalence guidance
Medicinal Product master data for better regulation and better health - Network Data Steering Group (NDSG) recommendations for human Product Master Data implementation and data management
Submitted by Anonymous (not verified) on 1 July 2025 - 11:02
Medicinal Product master data for better regulation and better health - Network Data Steering Group (NDSG) recommendations for human Product Master Data implementation and data management
Annual accounts: Financial year 2024
Submitted by Anonymous (not verified) on 1 July 2025 - 10:28
Annual accounts: Financial year 2024
Declaration on the qualification of an enterprise as a micro, small or medium-sized enterprise (SME)
Submitted by Anonymous (not verified) on 1 July 2025 - 10:18
Declaration on the qualification of an enterprise as a micro, small or medium-sized enterprise (SME)
Transparency: exceptional measures for COVID-19 medicines
Submitted by Anonymous (not verified) on 30 June 2025 - 16:00
Transparency: exceptional measures for COVID-19 medicines
Orphan designation: Humanised IgG1 monoclonal antibody against human epidermal growth factor receptor 2 Treatment of gastric cancer, 22/05/2025 Positive
Submitted by Anonymous (not verified) on 30 June 2025 - 15:22
Orphan designation: Humanised IgG1 monoclonal antibody against human epidermal growth factor receptor 2 Treatment of gastric cancer, 22/05/2025 Positive
Human medicines European public assessment report (EPAR): BroPair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 30 June 2025 - 15:20
Human medicines European public assessment report (EPAR): BroPair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 4, Status: Authorised
Orphan designation: Taladegib Treatment of idiopathic pulmonary fibrosis, 22/05/2025 Positive
Submitted by Anonymous (not verified) on 30 June 2025 - 15:02
Orphan designation: Taladegib Treatment of idiopathic pulmonary fibrosis, 22/05/2025 Positive